Veru Inc (NASDAQ:VERU) is set to release its Q2 2025 earnings on May 8, 2025. The consensus estimate for Q2 2025 revenue is $0.58 million, and the earnings are expected to come in at -$0.06 per share.

Veru Inc (VERU) showcases positive Phase IIb trial outcomes and a strong cash position, but faces ongoing financial hurdles and competitive market pressures.

Veru and its shareholders had high hopes for sabizabulin, an orally administered COVID treatment. These hopes were diminished greatly on Wednesday, when a Food and Drug Administration (FDA) advisory ...

Investors are always looking for stocks that are poised to beat at earnings season and Veru Inc. VERU may be one such company. The firm has earnings coming up pretty soon, and events are shaping up ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced ...

Insiders were net buyers of Veru Inc.'s (NASDAQ:VERU ) stock during the past year. That is, insiders bought more stock than they sold. While we would never suggest that investors should base their ...

NEW YORK - Veru Inc. (NASDAQ:VERU), a late clinical-stage biopharmaceutical company currently trading at $3.59 per share, has selected Laxxon Medical Corp.’s proprietary SPID (Screen Printing ...

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter.